397 related articles for article (PubMed ID: 31484560)
41. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
[TBL] [Abstract][Full Text] [Related]
42. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
43. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
[TBL] [Abstract][Full Text] [Related]
44. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies.
Ukleja J; Kusaka E; Miyamoto DT
Front Oncol; 2021; 11():663852. PubMed ID: 34041029
[TBL] [Abstract][Full Text] [Related]
46. [Immunotherapy in uropathology].
Verkarre V; Roussel H; Granier C; Tartour E; Allory Y
Ann Pathol; 2017 Feb; 37(1):90-100. PubMed ID: 28111042
[TBL] [Abstract][Full Text] [Related]
47. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
48. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Pharmacotherapy; 2017 Nov; 37(11):1391-1405. PubMed ID: 28950037
[TBL] [Abstract][Full Text] [Related]
49. Biologic response modifiers in genitourinary neoplasia.
Droller MJ
Cancer; 1987 Aug; 60(3 Suppl):635-44. PubMed ID: 2439187
[TBL] [Abstract][Full Text] [Related]
50. A review of checkpoint inhibitors in the management of renal cell carcinoma.
Hanna KS
J Oncol Pharm Pract; 2020 Mar; 26(2):445-458. PubMed ID: 31631812
[TBL] [Abstract][Full Text] [Related]
51. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
52. Latest progress in molecular biology and treatment in genitourinary tumours.
González-Del-Alba A; Arranz JÁ; Bellmunt J; Maroto JP; Fernández-Calvo O; Valderrama BP; González-Billalabeitia E; Méndez-Vidal MJ; Cassinello J; Romero-Laorden N; Climent MÁ; Puente J; Peláez I; Lázaro-Quintela M; Gallardo E; Suárez C
Clin Transl Oncol; 2020 Dec; 22(12):2175-2195. PubMed ID: 32440915
[TBL] [Abstract][Full Text] [Related]
53. Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740533
[TBL] [Abstract][Full Text] [Related]
54. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
Bigot F; Bonnet C; Massard C
Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
[TBL] [Abstract][Full Text] [Related]
55. Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors.
Carrozza F; Santoni M; Piva F; Cheng L; Lopez-Beltran A; Scarpelli M; Montironi R; Battelli N; Tamberi S
Crit Rev Oncol Hematol; 2018 Nov; 131():1-6. PubMed ID: 30293699
[TBL] [Abstract][Full Text] [Related]
56. Top advances of the year: Genitourinary cancer.
Jackson-Spence F; Young M; Sweeney C; Powles T
Cancer; 2023 Sep; 129(17):2603-2609. PubMed ID: 37378532
[TBL] [Abstract][Full Text] [Related]
57. Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.
Dallos MC; Drake CG
Cancer J; 2018; 24(1):20-30. PubMed ID: 29360724
[TBL] [Abstract][Full Text] [Related]
58. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
60. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
McGregor BA; Campbell MT; Xie W; Farah S; Bilen MA; Schmidt AL; Sonpavde GP; Kilbridge KL; Choudhury AD; Mortazavi A; Shah AY; Venkatesan AM; Bubley GJ; Siefker-Radtke AO; McKay RR; Choueiri TK
Cancer; 2021 Mar; 127(6):840-849. PubMed ID: 33216356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
